Literature DB >> 25062669

Venous thromboembolism in high grade glioma among surgical patients: results from a single center over a 10 year period.

Timothy R Smith1, Rishi R Lall, Randall B Graham, Jamal Mcclendon, Rohan R Lall, Allan D Nanney, Joseph G Adel, Anaadriana Zakarija, James P Chandler.   

Abstract

Patients with high-grade glioma are at elevated risk of venous thromboembolism (VTE). The relationship between VTE and survival in glioma patients remains unclear, as does the optimal protocol for chemoprophylaxis. The purpose of this study was to assessthe incidence of and risk factors associated with VTE in patients with high-grade glioma, and the correlation between VTE and survival in this population. Furthermore, we sought to define a protocol for perioperative DVT prophylaxis. This was a retrospective review of patients who underwent craniotomy for resection of high-grade glioma (WHO grade III or IV) at Northwestern University between 1999 and 2010. A total of 336 patients met inclusion criteria. 53 patients developed postoperative VTE (15.7 %). Median survival was 12.0 months and was not significantly different between VTE(+) and VTE(-) patients. Demographics and surgical factors were not significantly correlated with VTE development. Prior history of VTE was highly predictive of postoperative VTE (OR 7.1, p < .01), as was seizure (OR 2.4, p = .005). Increased duration of postoperative ICU stay was also a risk factor for VTE (p = .025). 25 patients in our study received prophylactic anticoagulation(pAC) with either heparin or enoxaparin. Early initiation of pAC was associated with decreased incidence of VTE (p = .042). There were no hemorrhagic complications in patients receiving pAC. VTE is a common complication in high-grade glioma patients. Early initiation of anticoagulation is safe and may decrease the risk of VTE. We recommend initiation of chemoprophylaxis on postoperative day 1 in patients without contraindication.

Entities:  

Mesh:

Year:  2014        PMID: 25062669     DOI: 10.1007/s11060-014-1557-4

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  25 in total

Review 1.  The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review.

Authors:  L C Marras; W H Geerts; J R Perry
Journal:  Cancer       Date:  2000-08-01       Impact factor: 6.860

2.  Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study.

Authors:  A A Brandes; E Scelzi; G Salmistraro; M Ermani; C Carollo; F Berti; P Zampieri; C Baiocchi; M V Fiorentino
Journal:  Eur J Cancer       Date:  1997-09       Impact factor: 9.162

Review 3.  Cancer and the prothrombotic state.

Authors:  Gregory Y H Lip; Bernard S P Chin; Andrew D Blann
Journal:  Lancet Oncol       Date:  2002-01       Impact factor: 41.316

4.  PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma.

Authors:  J R Perry; J A Julian; N J Laperriere; W Geerts; G Agnelli; L R Rogers; M G Malkin; R Sawaya; R Baker; A Falanga; S Parpia; T Finch; M N Levine
Journal:  J Thromb Haemost       Date:  2010-09       Impact factor: 5.824

Review 5.  Deep vein thrombosis and its prevention in critically ill adults.

Authors:  J Attia; J G Ray; D J Cook; J Douketis; J S Ginsberg; W H Geerts
Journal:  Arch Intern Med       Date:  2001-05-28

6.  Venous thromboembolism and survival in patients with high-grade glioma.

Authors:  Ralph Simanek; Rainer Vormittag; Marco Hassler; Karl Roessler; Martin Schwarz; Christoph Zielinski; Ingrid Pabinger; Christine Marosi
Journal:  Neuro Oncol       Date:  2007-02-27       Impact factor: 12.300

7.  Thromboembolic disease in patients with high-grade glioma.

Authors:  James R Perry
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

8.  Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis.

Authors:  E Bastida; A Ordinas; G Escolar; G A Jamieson
Journal:  Blood       Date:  1984-07       Impact factor: 22.113

Review 9.  Venous thromboembolism in malignant gliomas.

Authors:  E O Jenkins; D Schiff; N Mackman; N S Key
Journal:  J Thromb Haemost       Date:  2009-11-13       Impact factor: 5.824

10.  Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases.

Authors:  Alex J Walker; Tim R Card; Joe West; Colin Crooks; Matthew J Grainge
Journal:  Eur J Cancer       Date:  2012-11-09       Impact factor: 9.162

View more
  15 in total

Review 1.  [Neuroanesthesia].

Authors:  K Engelhard
Journal:  Anaesthesist       Date:  2016-02       Impact factor: 1.041

2.  Predictors of Venous Thromboembolism After Nonemergent Craniotomy: A Nationwide Readmission Database Analysis.

Authors:  Ian A Buchanan; Michelle Lin; Daniel A Donoho; Arati Patel; Li Ding; Arun P Amar; Steven L Giannotta; William J Mack; Frank Attenello
Journal:  World Neurosurg       Date:  2018-11-20       Impact factor: 2.104

Review 3.  Venous thromboembolism prophylaxis in brain tumor patients undergoing craniotomy: a meta-analysis.

Authors:  Nasser Alshehri; David J Cote; M Maher Hulou; Ahmad Alghamdi; Ali Alshahrani; Rania A Mekary; Timothy R Smith
Journal:  J Neurooncol       Date:  2016-09-03       Impact factor: 4.130

Review 4.  Venous thromboembolic events in patients undergoing craniotomy for tumor resection: incidence, predictors, and review of literature.

Authors:  Lorenzo Rinaldo; Desmond A Brown; Adip G Bhargav; Aaron E Rusheen; Ryan M Naylor; Hannah E Gilder; Dileep D Monie; Stephanie J Youssef; Ian F Parney
Journal:  J Neurosurg       Date:  2019-01-04       Impact factor: 5.115

Review 5.  Venous Thrombotic Events and Anticoagulation in Brain Tumor Patients.

Authors:  Maria Diaz; Jasmin Jo
Journal:  Curr Oncol Rep       Date:  2022-02-18       Impact factor: 5.075

6.  Mutant IDH1 and thrombosis in gliomas.

Authors:  Dusten Unruh; Steven R Schwarze; Laith Khoury; Cheddhi Thomas; Meijing Wu; Li Chen; Rui Chen; Yinxing Liu; Margaret A Schwartz; Christina Amidei; Priya Kumthekar; Carolina G Benjamin; Kristine Song; Caleb Dawson; Joanne M Rispoli; Girish Fatterpekar; John G Golfinos; Douglas Kondziolka; Matthias Karajannis; Donato Pacione; David Zagzag; Thomas McIntyre; Matija Snuderl; Craig Horbinski
Journal:  Acta Neuropathol       Date:  2016-09-23       Impact factor: 17.088

Review 7.  Venous Thromboembolism in Brain Tumors: Risk Factors, Molecular Mechanisms, and Clinical Challenges.

Authors:  Julia Riedl; Cihan Ay
Journal:  Semin Thromb Hemost       Date:  2019-04-30       Impact factor: 4.180

8.  Venous thromboembolism and intracranial hemorrhage after craniotomy for primary malignant brain tumors: a National Surgical Quality Improvement Program analysis.

Authors:  Joeky T Senders; Nicole H Goldhaber; David J Cote; Ivo S Muskens; Hassan Y Dawood; Filip Y F L De Vos; William B Gormley; Timothy R Smith; Marike L D Broekman
Journal:  J Neurooncol       Date:  2017-10-16       Impact factor: 4.130

9.  Acute care in glioblastoma: the burden and the consequences.

Authors:  Andrea Wasilewski; Jennifer Serventi; Lily Kamalyan; Thomas Wychowski; Nimish Mohile
Journal:  Neurooncol Pract       Date:  2017-03-08

10.  Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype.

Authors:  Maria Diaz; Jasmin Jo; Mark Smolkin; Sarah Jane Ratcliffe; David Schiff
Journal:  Neurology       Date:  2020-12-22       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.